| VTRS |
Report |
Q2 Adjusted EPS |
BEAT |
pred ~$0.66 vs. cons $0.62 |
MEDIUM |
| VTRS |
Report |
Q2 Total Revenue |
BEAT |
pred ~$3.73B vs. cons $3.68B |
MEDIUM |
| VTRS |
Report |
Q2 Adjusted EBITDA |
BEAT |
pred ~$1.06B vs. cons $1.02B |
MEDIUM |
| VTRS |
Guide |
FY2026 Adjusted EPS guidance |
BETTER |
guide raised to ~$2.42-2.50 (mid ~$2.46) vs. cons $2.46 (FY2026); prior $2.33-2.47 |
LOW |
| VTRS |
Guide |
FY2026 Total Revenue guidance |
BETTER |
guide raised to ~$14.7-15.0B (mid ~$14.80B) vs. cons $14.75B (FY2026); prior mid ~$14.70B |
LOW |
| VTRS |
Guide |
FY2026 Adjusted EBITDA guidance |
BETTER |
guide raised to mid ~$4.35B vs. cons $4.30B (FY2026); prior mid ~$4.30B |
LOW |
| VTRS |
Guide |
Greater China operational growth |
BETTER |
pred ~+12% YoY vs. cons/plan ~+6% (Q2/FY2026) |
MEDIUM |
| VTRS |
Guide |
New product revenue ramp |
UNCHANGED |
pred ~$110M in Q2 tracking to ~$450-550M vs. cons ~$500M (FY2026) |
MEDIUM |
| VTRS |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.5% |
— |
MEDIUM |
| VTRS |
Return |
5-day cumulative residual |
+0.0% (FADE) |
Beat is largely priced after a ~42% YTD run to 52-week highs; the swing factor is whether management raises vs. reaffirms FY guide. A modest/narrow raise (or reaffirm-only) with H2-weighted phasing means the implied 2H guide is effectively trimmed after the Q2 beat, so out-period estimate math caps upside and the initial pop fades back toward flat as the richly-valued, low-beta name digests limited fresh upside. |
LOW |